Biomembrane CEB-01 is manufactured from biocompatible, bioabsorbable nanofibers and locally, safely releases high doses of a chemotherapy drug (SN-38 that is currently administered in conventional chemotherapy). It is implanted over the surgical site after tumour removal. The goal is to eliminate any remains of tumour cells that could have been left, improve patients’ prognoses and reduce the secondary effects of oncology treatment, especially those of radiotherapy in childhood cancer. This innovative treatment tackles a medical need that is not covered in oncology.
Cebiotex wants to provide tools for cancer surgeons to apply a non-invasive therapy for childhood cancer and other rare diseases. The aim is to ensure that the surgical site remains free of cancerous cells after the removal of a tumour, to prevent its reproduction and the secondary effects of chemotherapy and, above all, radiotherapy in the case of paediatric patients.
The technology platform Cebiotex® and the biomembrane CEB-01 are patented in the United States, the European Union and China. In addition, Cebiotex has GMP (Good Manufacturing Practices) certification from the Spanish Agency of Medicines and Medical Products (AEMPS), which means that it can manufacture to pharmaceutical quality and implant its biomembranes in humans. In 2019, it obtained Orphan Drug Designation (ODD) in soft tissue sarcomas from the European Medical Agency (EMA) and the European Commission, certification that has advantages such as exclusivity of the EU market, and that facilitate the acceleration of its development for application in childhood cancer and rare diseases.
Cebiotex has launched a funding round to raise 1.6 million euros. The funds will be used to advance the development of this innovative oncological treatment, and finance Clinical Phase 2a, which will consist of implanting CEB-01 in 21 adult patients with soft tissue sarcoma at the Hospital de la Santa Creu i Sant Pau, and subsequently the main objective of starting clinical studies with pediatric patients at the Hospital Sant Joan de Déu. In the future, it is expected that the technology platform Cebiotex®, which is unique in the market, can be applied to other types of cancer, infections and advanced therapies. In the current round, investments are accepted from a thousand euros and all types of contributions.
The spin off Cebiotex was created in 2012 within the context of science and technology transfer of the INTEXTER institute of the UPC and the Hospital Sant Joan de Déu.